On November 11, Zhifei Biological Products Co., Ltd.(300122) issued an announcement stating that the company recently received approval from the National Medical Products Administration to allow its wholly-owned subsidiary to conduct clinical trials of its adsorbed acellular pertussis-diphtheria-tetanus (diphtheria-tetanus) combined vaccine (for adults and adolescents).
　　This vaccine aims to prevent infectious diseases such as diphtheria, tetanus, and pertussis, filling the market gap in domestic DPT (diphtheria, pertussis, and tetanus) vaccines for adolescents and adults. This approval marks a significant advancement for the company in vaccine development; the adolescent and adult DPT vaccine is a new generation of acellular vaccine, using separately purified active ingredients.
　　The company stated that if the clinical trials proceed smoothly, it will further enhance its market competitiveness, enrich its product line, and lay the foundation for long-term development. While this approval will not have a significant impact on near-term performance, future product development progress will improve the company's profitability and core competitiveness.
　　In the first three quarters of 2025, Zhifei Biological Products achieved revenue of 7.627 billion yuan and net profit attributable to the parent company of -1.206 billion yuan.

https://finance.eastmoney.com/a/202511113561071384.html